Drugs by condition
Drugs approved for small cell lung cancer
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
84
Still marketed, NDA or BLA
Drug classes
12
Novel drugs
47
New molecular entities and new biologics
In development
40+
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for small cell lung cancer.
- Jideytro (Zidesamtinib) · Nuvalent NovelOrphanJul 22, 2026
- Avopef (Etoposide) · Avyxa Holdings Feb 13, 2026
- Rybrevant Faspro (Amivantamab and Hyaluronidase-Lpuj) · Janssen Biotech Priority reviewDec 17, 2025
- Hyrnuo (Sevabertinib) · Bayer Healthcare NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanNov 19, 2025
- Keytruda Qlex (Pembrolizumab, Berahyaluronidase Alfa-Pmph) · Merck Sharp Dohme NovelAccelerated approvalPriority reviewSep 19, 2025
All approved drugs for small cell lung cancer, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 68 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Kinase Inhibitor (14)
- Hernexeos Zongertinib · Boehringer Ingelheim · 2025
- Lazcluze Lazertinib Mesylate · Janssen Biotech · 2024
- Augtyro Repotrectinib · Bristol · 2023
- Gavreto Pralsetinib · Rigel Pharms · 2020
- Retevmo Selpercatinib · Eli Lilly and CO · 2020
- Lorbrena Lorlatinib · Pfizer · 2018
- Alunbrig Brigatinib · Takeda Pharms USA · 2017
- Tagrisso Osimertinib Mesylate · Astrazeneca · 2015
- Gilotrif Afatinib Dimaleate · Boehringer Ingelheim · 2013
- Xalkori Crizotinib · Pf Prism Cv · 2011
- Retevmo Selpercatinib · Eli Lilly and CO · 2024
- Xalkori Crizotinib · Pf Prism Cv · 2023
- Zykadia Ceritinib · Novartis · 2019
- Iressa Gefitinib · Astrazeneca · 2015
Vascular Endothelial Growth Factor Inhibitor (6)
Microtubule Inhibitor (6)
- Beizray Docetaxel · Zhuhai · 2024
- Paclitaxel Paclitaxel · Teva Pharms INC · 2023
- Paclitaxel Paclitaxel · Am Regent · 2022
- Docetaxel Docetaxel · Accord Hlthcare · 2011
- Docetaxel Docetaxel · Hospira INC · 2011
- Abraxane Paclitaxel · Bristol-Myers · 2005
Programmed Death Receptor-1 Blocking Antibody (4)
- Tecentriq Atezolizumab · Genentech INC · 2016
- Opdivo Nivolumab · Bristol Myers Squibb · 2014
- Keytruda Pembrolizumab · Merck Sharp Dohme · 2014
- Tecentriq Hybreza Atezolizumab and Hyaluronidase-Tqjs · Genentech INC · 2024
Endoglycosidase (3)
- Keytruda Qlex Pembrolizumab, Berahyaluronidase Alfa-Pmph · Merck Sharp Dohme · 2025
- Rybrevant Faspro Amivantamab and Hyaluronidase-Lpuj · Janssen Biotech · 2025
- Opdivo Qvantig Nivolumab, Hyaluronidase-Nvhy · Bristol-Myers Squibb · 2024
CTLA-4-directed Blocking Antibody (2)
Topoisomerase Inhibitor (2)
Alkylating Drug (1)
- Zepzelca Lurbinectedin · Jazz · 2020
Programmed Death Ligand-1 Blocker (1)
- Imfinzi Durvalumab · Astrazeneca Uk LTD · 2017
Vascular Endothelial Growth Factor Receptor 2 Antagonist (1)
- Cyramza Ramucirumab · Eli Lilly and CO · 2014
Folate Analog Metabolic Inhibitor (1)
- Axtle Pemetrexed Dipotassium · Avyxa Holdings · 2024
Class not listed in FDA's data (43)
- Jideytro Zidesamtinib · Nuvalent · 2026
- Hyrnuo Sevabertinib · Bayer Healthcare · 2025
- Zegfrovy Sunvozertinib · Dizal · 2025
- Ibtrozi Taletrectinib Adipate · Nuvation · 2025
- Emrelis Telisotuzumab Vedotin-Tllv · Abbvie INC · 2025
- Datroway Datopotamab Deruxtecan-Dlnk · Daiichi Sankyo INC · 2025
- Ensacove Ensartinib Hydrochloride · Xcovery · 2024
- Bizengri Zenocutuzumab-Zbco · Merus N.V. · 2024
- Imdelltra Tarlatamab-Dlle · Amgen INC · 2024
- Krazati Adagrasib · Bristol · 2022
- Lumakras Sotorasib · Amgen INC · 2021
- Rybrevant Amivantamab-Vmjw · Janssen Biotech · 2021
- Cosela Trilaciclib Dihydrochloride · Pharmacosmos · 2021
- Tepmetko Tepotinib Hydrochloride · Emd Serono INC · 2021
- Tabrecta Capmatinib Hydrochloride · Novartis Pharm · 2020
- Enhertu Fam-Trastuzumab Deruxtecan-Nxki · Daiichi Sankyo · 2019
- Rozlytrek Entrectinib · Genentech INC · 2019
- Libtayo Cemiplimab-Rwlc · Regeneron Pharmaceuticals · 2018
- Braftovi Encorafenib · Array Biopharma INC · 2018
- Mektovi Binimetinib · Array Biopharma INC · 2018
- Alecensa Alectinib Hydrochloride · Hoffmann-La Roche · 2015
- Tafinlar Dabrafenib Mesylate · Novartis · 2013
- Mekinist Trametinib Dimethyl Sulfoxide · Novartis · 2013
- Alimta Pemetrexed Disodium · Lilly · 2004
- Hycamtin Topotecan Hydrochloride · Sandoz · 1996
- Taxotere Docetaxel · Sanofi Aventis US · 1996
- Photofrin Porfimer Sodium · Pinnacle Biolgs · 1995
- Avgemsi Gemcitabine Hydrochloride · Avyxa Holdings · 2025
- Rozlytrek Entrectinib · Genentech INC · 2023
- Pemetrexed Pemetrexed Disodium · Shilpa · 2023
- Mekinist Trametinib, Trametinib Dimethyl Sulfoxide · Novartis · 2023
- Tafinlar Dabrafenib Mesylate · Novartis · 2023
- Docetaxel Docetaxel · Avyxa Holdings · 2022
- Pemetrexed Disodium Pemetrexed Disodium · Hospira · 2022
- Pemetrexed Disodium Pemetrexed Disodium · Sandoz · 2022
- Pemetrexed Pemetrexed · Actavis · 2020
- Pemfexy Pemetrexed · Eagle Pharms · 2020
- Docetaxel Docetaxel · Actavis · 2013
- Gemcitabine Hydrochloride Gemcitabine Hydrochloride · Hospira INC · 2011
- Docetaxel Docetaxel · Sandoz · 2011
- Topotecan Hydrochloride Topotecan Hydrochloride · Hospira INC · 2011
- Hycamtin Topotecan Hydrochloride · Sandoz · 2007
- Etopophos Preservative Free Etoposide Phosphate · Cheplapharm · 1996
Drugs in development for small cell lung cancer
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- PF-08634404SSGJ-707Phase 312 trials
Pfizer · Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC)
- ZimberelimabAB122, GS-0122Phase 312 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
More on small cell lung cancer: recruiting trials · published research
Related in oncology: Breast cancer · Non-small cell lung cancer · Prostate cancer · Colorectal cancer · Melanoma · Ovarian cancer · Pancreatic cancer · Bladder and urothelial cancer · Kidney cancer (renal cell carcinoma) · Liver cancer (hepatocellular carcinoma)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.